Big Pharma's Patient Last Playbook & the Battle for Minnesota and the SAVE Act
The House Energy and Commerce Committee will hold a healthcare affordability hearing on Thursday, February 12, focused on the pharmaceutical supply chain, even as drugmakers raised prices on nearly 1,000 prescription drugs this January, and pharmaceutical CEOs are not expected to testify. Why is Big Pharma's "patient-last" playbook continuing despite the recent White House deals? What do lawmakers risk overlooking if drug manufacturers are not at the witness table? As lawmakers revisit the topic of affordability, it's critical they remember …
Þessi þáttur hefur ekki verið afritaður ennþá
Notaðu STT.ai til að afrita þennan þátt með AI.Fáðu nákvæman texta með hátalaragreiningu, tímastimpil og flytja út í mörgum sniðum.